Otsuka Holdings (4578) Report Interpretation

Overview

This first-take note assesses Otsuka Holdings' detailed two-year Phase 3 VISIONARY data for Voyxact (sibeprenlimab) in IgA nephropathy. Goldman Sachs considers the efficacy and safety results positive, maintains Buy, and says the evidence raises expectations that the drug could become a blockbuster.

Core views

Otsuka HD presented the full two-year Phase 3 VISIONARY results for its anti-APRIL antibody Voyxact (sibeprenlimab) at GlomCon Hawaii 2026 on August 4 JST. Goldman Sachs highlights the annualized slope of estimated glomerular filtration rate (eGFR), a measure of kidney-function change over time, as the most closely watched endpoint. At 24 months, the slope was +0.3 mL/min/1.73 m²/year for sibeprenlimab, compared with -4.2 for placebo, producing a 4.5 mL/min/1.73 m²/year treatment difference. The respective 95% confidence intervals were -0.4 to +0.9, -4.9 to -3.6, and +3.6 to +5.4. Goldman Sachs regards the +0.3 result as favorable both against the trial's 12-month slope of -3.0 and against a normal annual kidney-function decline of less than 1 mL/min/1.73 m²/year. The second efficacy measure also favored the drug. The least-squares mean change in eGFR from baseline at 24 months was +1.3 mL/min/1.73 m² for sibeprenlimab, versus -7.9 for placebo, a 9.2 mL/min/1.73 m²/year treatment difference with p<0.0001. The associated 95% confidence intervals were -0.3 to +2.8 for the treatment group, -9.5 to -6.4 for placebo, and +7.1 to +11.4 for the difference. Goldman Sachs says the stable favorable eGFR trend from baseline and the improvement from the 12-month data support high competitiveness versus existing and competing drugs, while explicitly cautioning that direct comparisons across different trials are not possible. Safety did not introduce a new concern in the report's assessment. Sibeprenlimab's safety profile was comparable with placebo, with no new safety issues identified. Serious infections occurred in 1.9% of the sibeprenlimab group versus 4.0% of the placebo group; serious or severe adverse events and treatment discontinuation also trended lower with sibeprenlimab. Goldman Sachs therefore argues that the updated data reinforce expectations that Voyxact can establish a first-mover advantage as a first-in-class treatment and potentially become a blockbuster. Goldman Sachs maintains its Buy rating and a 12-month ¥14,000 target price. The target is based on a 12-year DCF model using a 6% WACC and a 0% terminal growth rate. The institution identifies further clinical data, potential US full approval and an auto-injector launch potentially in 1H 2027, and treatment-guideline revisions as potential drivers of faster market penetration. It also flags the market response following competing-product launches: atacicept was approved on July 7, while povetacicept has a November 30 PDUFA date. The report's accompanying forecasts show revenue of ¥2,468.9bn in 12/25, ¥2,736.0bn in 12/26E, ¥2,621.0bn in 12/27E, and ¥2,660.4bn in 12/28E. Forecast operating profit is ¥479.4bn, ¥473.8bn, ¥406.8bn, and ¥446.7bn, respectively; EPS is ¥685.1, ¥684.8, ¥658.2, and ¥732.1. Forecast P/E is 11.3x, 16.8x, 17.5x, and 15.7x, while forecast dividend yield is 1.8%, 1.7%, 1.7%, and 1.7%, respectively.

Analysis framework

Goldman Sachs evaluates the detailed two-year VISIONARY clinical endpoints against placebo, the trial's earlier 12-month data, and a stated normal rate of kidney-function decline. It then connects efficacy and safety findings to Voyxact's competitive positioning and potential market penetration, while valuing Otsuka HD with a 12-year discounted-cash-flow model.

Methodology notes

• Valuation methodsDCF (Discounted Cash Flow)

  12-year discounted cash flow model

  The target price is derived by discounting projected cash flows over 12 years using a 6% WACC and a 0% terminal growth rate.

• Other

  Placebo-controlled Phase 3 clinical-trial endpoint comparison

  The report compares 24-month eGFR outcomes for sibeprenlimab with placebo and with the trial's earlier 12-month data to assess efficacy and competitive potential.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Otsuka HD (4578.T)

  Primary covered company; the report links the favorable Voyxact data to stronger blockbuster expectations and maintains Buy.

  Strengths

  Voyxact showed favorable two-year eGFR outcomes versus placebo, no new safety concerns, and potential first-mover advantage as a first-in-class drug.

  Comparison

  Goldman Sachs considers the data suggestive of high competitiveness versus existing and competing drugs, but notes that direct cross-trial comparisons are not possible.

  Risks

  Key-drug sales weakness or suspension, development delays or suspension, nutraceuticals risks, slower new-market creation, and divergence from DCF assumptions.

Key data

• 24-month annualized eGFR slope+0.3 mL/min/1.73 m²/year for sibeprenlimab; -4.2 for placebo; difference 4.595% CIs: -0.4 to +0.9, -4.9 to -3.6, and +3.6 to +5.4, respectively.
• 24-month eGFR change from baseline+1.3 mL/min/1.73 m² for sibeprenlimab; -7.9 for placebo; difference 9.2p<0.0001; treatment-difference 95% CI: 7.1 to 11.4.
• Serious infection incidence1.9% for sibeprenlimab; 4.0% for placeboNo new safety concerns were reported.
• Target-price assumptions¥14,000; 12-year DCF; 6% WACC; 0% terminal growthGoldman Sachs' stated 12-month target-price methodology.
• Revenue forecast¥2,468.9bn (12/25), ¥2,736.0bn (12/26E), ¥2,621.0bn (12/27E), ¥2,660.4bn (12/28E)Goldman Sachs forecasts.
• Operating-profit forecast¥479.4bn (12/25), ¥473.8bn (12/26E), ¥406.8bn (12/27E), ¥446.7bn (12/28E)Goldman Sachs forecasts.
• EPS forecast¥685.1 (12/25), ¥684.8 (12/26E), ¥658.2 (12/27E), ¥732.1 (12/28E)Goldman Sachs forecasts.

Impact & implications

Goldman Sachs believes the two-year efficacy and safety profile increases the likelihood that Voyxact can secure a strong competitive position in IgA nephropathy. Its outlook depends on subsequent clinical evidence, US regulatory and delivery-device milestones, guideline changes, and the evolving competitive market.

Risks

• Sales of key drugs could be weaker than expected or could be suspended.
• Drug development could be suspended or delayed.
• The nutraceuticals business could be adversely affected by unfavorable weather or a greater-than-expected inflation impact.
• New-market creation could proceed more slowly than expected.
• Outcomes could diverge from Goldman Sachs' DCF assumptions.

What to watch

• Additional clinical-trial data that could accelerate Voyxact's market penetration.
• Potential US full approval and the potential US auto-injector launch in 1H 2027.
• Treatment-guideline revisions.
• Market developments after atacicept's July 7 approval and the November 30 PDUFA date for povetacicept.